Uncategorized
calendar_month Nov 17, 2026

Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies

Eli Lilly and Co. (NYSE:LLY) entered a strategic research collaboration and licensing agreement with privately held biotechnology company Stipple Bio Inc. on Monday to develop targeted cancer therapies.

The agreement covers multiple drug targets and therapeutic approaches, with Stipple Bio eligible to receive up to $5.9 billion in milestone payments, along with royalties on potential product sales.

Deal Terms

Under the agreement, Stipple Bio will receive an upfront payment and an equity investment from Eli Lilly. The companies did not disclose the amounts.

Eli Lilly will secure exclusive worldwide rights to develop and commercialize products arising from the collaboration.

Meanwhile, Stipple Bio will be eligible for payments tied to research, product development and commercialization milestones. It could also receive tiered royalties if Eli Lilly successfully commercializes the therapies.

Advancing Precision Cancer Treatments

Stipple Bio will use its proprietary Pointillist Platform to identify novel binding molecules that recognize specific sites, known as epitopes, on tumor cell surfaces.

Eli Lilly will combine these discoveries with its proprietary oncology technologies to develop cancer treatments across multiple therapeutic approaches.

The collaboration aims to improve treatment effectiveness while reducing damage to healthy tissue. Such toxicity has historically limited the clinical use of certain cancer drug targets.

Stipple Bio CEO Jeff Landau said Eli Lilly’s oncology research and drug development expertise could help advance more precise cancer treatments.

He added that the partnership would allow Stipple Bio to expand the therapeutic applications of its platform while continuing to develop its own pipeline.

Stipple Bio’s Funding and Clinical Development

In April, Stipple Bio raised $100 million in an oversubscribed Series A funding round to support early-stage clinical studies of STP-100 and expand its precision oncology pipeline using the Pointillist Platform.

The company plans to initiate a Phase 1 clinical trial in early 2027 for STP-100, its lead antibody-drug conjugate candidate for solid tumors, including pancreatic cancer.

Stipple Bio also recently earned a spot on the 2026 Endpoints 11, an annual selection of promising privately held biotechnology companies.

Eli Lilly Expands Drug Development Portfolio

Separately, Eli Lilly agreed Monday to acquire Calytrix Bio Inc. for up to $1.5 billion in cash.

The agreement includes an upfront cash payment to Calytrix shareholders and additional payments tied to clinical and regulatory milestones.

Calytrix develops precision therapies for myeloproliferative neoplasms, a group of blood cancers characterized by the overproduction of blood cells.

LLY Price Action: Eli Lilly shares were down 1.17% at $1414.87 at the time of publication on Tuesday, according to Benzinga Pro data.

Image via Shutterstock